
Vicarious Surgical (RBOT) Stock Forecast & Price Target
Vicarious Surgical (RBOT) Analyst Ratings
Bulls say
Vicarious Surgical Inc has demonstrated effective expense management, with a total operating expense of $17.7 million in Q2 reflecting a 17% decrease year-over-year, which is indicative of the company's commitment to financial discipline. The company's research and development expenditures of $8.5 million were significantly lower than projected, suggesting more efficient use of resources in advancing technology. Moreover, the reaffirmation of the timeline for the Vicarious Surgical Robotic System's version 1.0 integration by fall 2024 underscores management's confidence in their technological advancements and projected commercialization goals.
Bears say
Vicarious Surgical Inc reported significant adjusted net losses in both the latest quarter and prior quarter, underscoring its struggles with profitability as the adjusted EPS of -$2.86 fell short of the Street's expectation of -$2.72. Elevated investment risk associated with the ongoing development of its surgical robot, coupled with concerns around potential future share dilution from equity financings, adds to the company’s financial challenges. The reduction in the company’s cash balance and increased share count also contributed to a lowered price target, reflecting a cautious outlook on long-term viability.
This aggregate rating is based on analysts' research of Vicarious Surgical and is not a guaranteed prediction by Public.com or investment advice.
Vicarious Surgical (RBOT) Analyst Forecast & Price Prediction
Start investing in Vicarious Surgical (RBOT)
Order type
Buy in
Order amount
Est. shares
0 shares